Wednesday, November 11, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 5, 2026

Stocks Pressured by Rising Oil Prices and Bond Yields

View original at nasdaq.com
Stocks Pressured by Rising Oil Prices and Bond Yields The S&P 500 Index ($SPX) (SPY) today is down -0.26%, the Dow Jones Industrial Average ($DOWI) (DIA) is down -0.80%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +0.16%…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Most of American Eagle Outfitters' profit will be generated in the second half of the year

    80% confidence
  • Inflation is a bigger concern than economic growth as ECB assesses implications of war in Iran

    80% confidence
  • Astera Labs rated buy with $250 price target

    80% confidence
  • S&P earnings growth expected to climb by 8.4% in Q4, marking tenth consecutive quarter of year-over-year growth

    80% confidence
  • Real-time risk premium for crude oil at $18/barrel, corresponding to impact of six-week full halt to tanker traffic in Strait of Hormuz

    80% confidence
  • Prolonged conflict in Middle East would risk pushing inflation expectations higher

    80% confidence
  • Ships sailing through Strait of Hormuz could be at risk from missiles or rogue drones

    80% confidence
  • Excluding Magnificent Seven megacap tech stocks, Q4 earnings expected to increase by 4.6%

    80% confidence
  • Four of six tanks at Saudi Arabia's Ras Tanura refinery were full, and Ju'aymah terminal is quickly running out of spare capacity

    80% confidence
  • Broadcom expects its AI chip sales to top $100 billion next year

    80% confidence
  • Fastenal February daily sales rate estimate of 7.2%

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,564 source documents archived
Query this data → isubstrate.com
Stocks Pressured by Rising Oil Prices and Bond Yields — Source | Via News | Via News